1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Rhinitis – Pipeline Review, H1 2013

Rhinitis – Pipeline Review, H1 2013

  • February 2013
  • -
  • Global Markets Direct
  • -
  • 46 pages

Rhinitis – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Rhinitis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Rhinitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rhinitis. Rhinitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Rhinitis.
- A review of the Rhinitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Rhinitis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Rhinitis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Rhinitis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Rhinitis - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Rhinitis Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Rhinitis 7
Rhinitis Therapeutics under Development by Companies 9
Rhinitis Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Rhinitis Therapeutics - Products under Development by Companies 15
Rhinitis Therapeutics - Products under Investigation by Universities/Institutes 16
Companies Involved in Rhinitis Therapeutics Development 17
GlaxoSmithKline plc 17
Meda AB 18
Revance Therapeutics, Inc. 19
Stallergenes S.A. 20
Allergopharma Joachim Ganzer KG 21
Rhinitis - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
SB-705498 - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
cetirizine hydrochloride - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
RT-001 - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
Acaroid - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Epicutaneous Allergen Patch - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
RT-401 - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
Ragweed Pollen Allergen Extract - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
(pseudoephedrine + levocetirizine) - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
Rhinitis Therapeutics - Drug Profile Updates 39
Rhinitis Therapeutics - Discontinued Products 41
Rhinitis Therapeutics - Dormant Products 42
Rhinitis - Product Development Milestones 43
Featured News and Press Releases 43
Jun 14, 2012: Shionogi Announces Initial Data From Phase IIb Study Of S-555739 43
Dec 22, 2011: Ampio Pharmaceuticals Receives Canadian Composition Of Matter Patent For Ampion 43
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 46
Disclaimer 46



List of Tables

Number of Products Under Development for Rhinitis, H1 2013 7
Products under Development for Rhinitis - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Number of Products under Investigation by Universities/Institutes, H1 2013 10
Comparative Analysis by Late Stage Development, H1 2013 11
Comparative Analysis by Mid Clinical Stage Development, H1 2013 12
Comparative Analysis by Early Clinical Stage Development, H1 2013 13
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 14
Products under Development by Companies, H1 2013 15
Products under Investigation by Universities/Institutes, H1 2013 16
GlaxoSmithKline plc, H1 2013 17
Meda AB, H1 2013 18
Revance Therapeutics, Inc., H1 2013 19
Stallergenes S.A., H1 2013 20
Allergopharma Joachim Ganzer KG, H1 2013 21
Assessment by Monotherapy Products, H1 2013 22
Assessment by Combination Products, H1 2013 23
Assessment by Stage and Route of Administration, H1 2013 25
Assessment by Stage and Molecule Type, H1 2013 27
Rhinitis Therapeutics - Drug Profile Updates 39
Rhinitis Therapeutics - Discontinued Products 41
Rhinitis Therapeutics - Dormant Products 42



List of Figures

Number of Products under Development for Rhinitis, H1 2013 7
Products under Development for Rhinitis - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Products under Investigation by Universities/Institutes, H1 2013 10
Late Stage Products, H1 2013 11
Mid Clinical Stage Products, H1 2013 12
Early Clinical Stage Products, H1 2013 13
Pre-Clinical Stage Products, H1 2013 14
Assessment by Monotherapy Products, H1 2013 22
Assessment by Combination Products, H1 2013 23
Assessment by Route of Administration, H1 2013 24
Assessment by Stage and Route of Administration, H1 2013 25
Assessment by Molecule Type, H1 2013 26
Assessment by Stage and Molecule Type, H1 2013 27

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...

Global Markets for Diabetes Therapeutics and Diagnostics

Global Markets for Diabetes Therapeutics and Diagnostics

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Analyze the market for drugs used in the treatment of diabetes, it's technology and the industry as a whole - Identify important trends and provide sales forecasts by product categories ...

Bovine Respiratory Disease Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Bovine Respiratory Disease Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • October 2016
  • by Transparency Market Research

Global Bovine Respiratory Disease Treatment Market: Overview Bovine respiratory disease (BRD) is a multifactorial and complex disorder caused due to combination of more than one microbial pathogens, impaired ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.